Member Info for latpulldown

To reflect the platinum standard technology that BRH has.

Great to see a climb in the sp today and back to normal trading.

Top quality product for detecting Covid19 more accurately and with high medical relevance as a bonus buy.

Buy one and get one free.

A nice cruise of the Med or the Caribbean for me when this signs a partner or gets taken over.

Unique technology like this is destined for those with bigger pockets and who can expedite.

The Government has 4 reviews ongoing behind the scenes of the Roadmap for unlocking the economy.

The one on social distancing and mask wearing etc is due to report back by the 17th June.

That's same day incidentally as the one that will be reporting back on whether or not it will be safe for large events to open up again.

2nd Interview explaining things more clearly was released yesterday

RNS.
https://www.lse.co.uk/rns/BRH/further-update-re-paraytec-limited-ktrgciyqh2vbs5m.html

1st Interview
https://www.youtube.com/watch?v=-M0O-JFoFUc

2nd Interview
https://www.proactiveinvestors.com/companies/news/943228/paraytec-lead-covid-19-professor-on-sensitivity-and-specificity-of-various-types-of-covid-19-tests-943228.html

*Less than 2 minutes
*Lends itself to mass testing crowds with only a fraction of otherwise individual tests (20 instead of 100)
*Can detect other life threatening diseases also - sepsis

Watch in conjunction with reading 1 March RNS.

https://www.proactiveinvestors.com/companies/news/943228/paraytec-lead-covid-19-professor-on-sensitivity-and-specificity-of-various-types-of-covid-19-tests-943228.html

Watch the Professor Smythe interviews and read the 1st March RNS.

All coming in sequential order and be grateful you can get in at this share price.

The questions you should be asking are,

1. As a globally marketed less than 2 minute Covid19 test how much is it worth in that market?
2. As a globally marketed Matrix testing device how much is it worth?
3. As a globally marketed medical testing device for Sepsis how much is it worth?

Let Professor Smythe work up the sensitivity and let us know in about 3 weeks time.

Cutting out the false positives and the false negatives and being far more accurate in detecting Covid (and other pathogens) is the Unique Selling Point (USP) of this product.

The falls were grossly overdone and particularly when you have such a game changing product. A 1.2 Million share sale (of 37 Million) does not merit such falls. All passed on as well.

Just a day of collecting all that could be collected under 33p.

Great news.

ArK87

We might get to hear a bit sooner than some think on improved sensitivity. fortunately we can all read the RNS for ourselves.

"In parallel to the sample processing described above, the Paraytec team has been using isolated lab-grown virus to optimise the operational sensitivity of its instrument for the detection of pre-symptomatic and early-stage symptomatic virus levels. It believes it will be able to confirm, within a period of four weeks, a lower limit of detection of 1,000 virions per millilitre of sample, also a market-leading value."

My thoughts exactly ArK87.

Talking of grate tools. Some on here gave up the full of their weekend trying to deramp and for the most part of today as well, and for their combined effort the share price has gone up 8.13%. What a complete and utter waste of time that was on their part.

We know that BRH has an industry leading test for Covid in terms of speed to results and in eliminating both false positives and false negatives and thereby increasing its accuracy over other tests. In a further 3 more weeks now we should have refined that accuracy further and improved on it even more.

Enhancing Sepsis diagnosis early from a medical viewpoint is in its own right a financial winner.

Buy One, Get One Free.

That professor knows his stuff and thats who's knowledge and explanations I'll be sticking with.

Nice of him and the interviewer to afford the time for a second interview. Very much appreciated.

I don't know about to the moon but it has significant potential.

No way that a 1.2 Million share sale (against 37 Million shares in issue) should have caused a near 40% fall in the share price. Real value being presented for those investing and who can work these things out.

Thank you Professor Smythe - so we have a product that knocks the socks off the others in terms of not only the time it takes to conduct the tests but that cuts out the number of false negatives and positives.

Detection of Sepsis and other killer diseases early a real bonus.

Seems to be positive from the share price reaction.

People will now be starting to have their eye on recovery around the world as vaccines rollout and work.

Another 2 year for an appeal would not be a bad thing if they don't have to pay out any monies now. I don't however know how to take the part in the RNS with the Judges discretion to potentially increase the sum. Is that the norm with these type of cases?

It's a big hit for sure if the judge endorses things and not the RNS I would have liked to wake up to. It will be interesting to see how our Us Investors digest it.